Is BAX stock overvalued right now?

Our multi-model fair value estimate of $28.35 suggests BAX may be undervalued by approximately 19.6% at the current price of $23.71.

What is BAX fair value based on current fundamentals?

Our fair value estimate for BAX is $28.35, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.

How risky is BAX compared with other stocks?

BAX carries a beta of 0.59 suggests a defensive profile. Investors should weigh macro exposure against their own risk tolerance.

Is BAX still growing?

Latest trailing metrics show revenue growth of 5.3% and earnings growth of 36.8%. Profit margins are not available.

What do analysts think about BAX?

Analyst consensus target is $28.73, implying 21.2% upside. The street recommendation is "hold".

Does BAX pay a dividend?

Yes. BAX currently offers a dividend yield of 0.2%.

What could change the investment case for BAX?

Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

HealthcareUpdated·Data: Yahoo Finance, SEC EDGAR·Data delayed ~5 min

Analysis BAX Valuation Check Momentum Leader FCF Positive

NYQ · Healthcare · Medical Instruments & Supplies

$23.71

-0.15 (-0.63%)

Stock valuation guide Macro risk explained guide

About the Author

Phasakorn Traklang (Peach) — Founder

Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.

Connect on LinkedIn

Investment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC

Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.